Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study

摘要: We aimed at evaluating whether the addition of low-dose metformin to dietary treatment could be an effective approach in nondiabetic patients with nonalcoholic fatty liver disease (NAFLD). carried out a 6-month prospective study series overweight or obese ultrasonographic diagnosis hepatic steatosis. In total, 50 were enrolled and randomized into two groups: first group (n=25) was given (1 g per day) plus second alone. At end study, proportion echographic evidence reduced both (P<0.0001) diet (P=0.029). Moreover, patient body mass index waist circumference significantly decreased groups (P<0.001). Fasting glucose, insulin resistance (evaluated as homeostasis model assessment (HOMA-IR)) serum adiponectin groups, although these changes reached statistical significance only group. this group, HOMA-IR from 3.3±1.6 2.4±1.2 (P=0.003), whereas it 3.2±1.6 2.8±1.1 (not significant, NS) Similarly, impaired fasting glucose declined 35 5% (P=0.04) 32 12% (NS) baseline, ∼40% met diagnostic criteria metabolic syndrome. This 20% (P=0.008) 32% (NS). our alone ameliorated steatosis derangements NAFLD. However, more than normalizing several parameters patients.